Veridex LLC has received FDA clearance to market the CellSearch(TM) Circulating Tumor Cell (CTC) Kit as an aid to monitoring patients suffering from metastatic prostate cancer. The CellSearch System had already been cleared for metastatic breast and metastatic colorectal cancer and counts CTCs in a patient’s blood sample to predict progression-free and overall survival. The CellSearch CTC Kit was developed by Immunicon Corporation and is exclusively marketed by Veridex.